Literature DB >> 25728312

Red yeast rice for the treatment of dyslipidemia.

Frances M Burke1.   

Abstract

Red yeast rice (RYR) is a Chinese herbal supplement produced by fermenting white rice with the yeast, Monascus purpureus. The Chinese have used RYR to flavor, color, and preserve foods and as a traditional medicine for many years. In the USA, RYR has been used as an alternative to statin therapy in treating patients with mild to moderate hypercholesterolemia. RYR contains a variety of monacolins, which inhibit hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. Consumption of RYR has increased recently especially among patients who might be intolerant to standardized therapy due to statin-associated myalgia (SAM). Several clinical trials have shown RYR to be safe, effective, and well tolerated; however, the studies are small and of short duration. The US Food and Drug Administration has prohibited the sale of all RYR products containing monacolin K, which is chemically identical to lovastatin, because it is considered an unapproved drug. However, many RYR supplements continue to remain on the market and lack standardization and quality control.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25728312     DOI: 10.1007/s11883-015-0495-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  26 in total

Review 1.  The role of red yeast rice for the physician.

Authors:  Ram Y Gordon; David J Becker
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

2.  Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!

Authors:  Ram Y Gordon; Tod Cooperman; William Obermeyer; David J Becker
Journal:  Arch Intern Med       Date:  2010-10-25

3.  Is red yeast rice safe and effective for lowering serum cholesterol?

Authors:  Eleese Cunningham
Journal:  J Am Diet Assoc       Date:  2011-02

4.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

5.  Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.

Authors:  Patrick M Moriarty; Eli M Roth; Adam Karns; Ping Ye; Shui-Ping Zhao; Yuhua Liao; David M Capuzzi; Harold E Bays; Fumin Zhang; Shaowen Liu; Alan J Reichman; Osvaldo A Brusco; Guoping Lu; Sam Lerman; Zhenwen Duan; Shuren Guo; Ping Lan Liu; Junxian Zhao; Yan Zhang; Simon Li
Journal:  J Clin Lipidol       Date:  2014-09-16       Impact factor: 4.766

6.  Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).

Authors:  Jian-Jun Li; Zong-Liang Lu; Wen-Rong Kou; Zuo Chen; Yang-Feng Wu; Xue-Hai Yu; Yu-Cheng Zhao
Journal:  J Clin Pharmacol       Date:  2009-08       Impact factor: 3.126

7.  Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products.

Authors:  Chia-Hao Chen; Jyh-Chin Yang; Yow-Shieng Uang; Chun-Jung Lin
Journal:  Int J Pharm       Date:  2013-01-23       Impact factor: 5.875

8.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

Review 9.  The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders.

Authors:  Clinton W Yang; Shaker A Mousa
Journal:  Complement Ther Med       Date:  2012-08-17       Impact factor: 2.446

10.  Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.

Authors:  Steven C Halbert; Benjamin French; Ram Y Gordon; John T Farrar; Kathryn Schmitz; Patti B Morris; Paul D Thompson; Daniel J Rader; David J Becker
Journal:  Am J Cardiol       Date:  2009-11-26       Impact factor: 2.778

View more
  15 in total

1.  Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system.

Authors:  Gabriela Mazzanti; Paola Angela Moro; Emanuel Raschi; Roberto Da Cas; Francesca Menniti-Ippolito
Journal:  Br J Clin Pharmacol       Date:  2017-01-19       Impact factor: 4.335

2.  Red Yeast Rice.

Authors:  Thu Nguyen; Mitchell Karl; Antonello Santini
Journal:  Foods       Date:  2017-03-01

3.  Statin-related Lichenoid Dermatosis: An Uncommon Adverse Reaction to a Common Treatment.

Authors:  Zsófia Vesza; Catarina Pires; Pedro Marques da Silva
Journal:  Eur J Case Rep Intern Med       Date:  2018-05-25

4.  Red Yeast Rice: A Systematic Review of the Traditional Uses, Chemistry, Pharmacology, and Quality Control of an Important Chinese Folk Medicine.

Authors:  Bo Zhu; Fangyuan Qi; Jianjun Wu; Guoqing Yin; Jinwei Hua; Qiaoyan Zhang; Luping Qin
Journal:  Front Pharmacol       Date:  2019-12-02       Impact factor: 5.810

Review 5.  The Use of Nutraceuticals to Counteract Atherosclerosis: The Role of the Notch Pathway.

Authors:  Giorgio Aquila; Luisa Marracino; Valeria Martino; Donato Calabria; Gianluca Campo; Cristiana Caliceti; Paola Rizzo
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

6.  Perspectives on Functional Red Mold Rice: Functional Ingredients, Production, and Application.

Authors:  Feng Yanli; Yu Xiang
Journal:  Front Microbiol       Date:  2020-11-25       Impact factor: 5.640

7.  Assimilation of Cholesterol by Monascus purpureus.

Authors:  Theresa P T Nguyen; Margaret A Garrahan; Sabrina A Nance; Catherine E Seeger; Christian Wong
Journal:  J Fungi (Basel)       Date:  2020-12-09

8.  Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial.

Authors:  Matteo Pirro; Massimo R Mannarino; Stefano Ministrini; Francesca Fallarino; Graziana Lupattelli; Vanessa Bianconi; Francesco Bagaglia; Elmo Mannarino
Journal:  Sci Rep       Date:  2016-03-23       Impact factor: 4.379

9.  Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial.

Authors:  Arrigo Francesco Giuseppe Cicero; Alessandro Colletti; Federica Fogacci; Marilisa Bove; Martina Rosticci; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-06-23

10.  Regulatory Status of Cannabidiol in the United States: A Perspective.

Authors:  Jamie Corroon; Rod Kight
Journal:  Cannabis Cannabinoid Res       Date:  2018-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.